Q&A with Alain Litwin, MD, from Albert Einstein College of Medicine: Studying and Overcoming Stigmas of Treating Injectable Drug Users with Hepatitis C

Video

One of the largest populations of patients with hepatitis C is those who use injectable drugs. Despite this, many of these patients do not receive the medications they need to treat their conditions.

One of the largest populations of patients with hepatitis C is those who use injectable drugs. Despite this many of these patients do not receive the medications they need to treat their conditions.

Alain H. Litwin, MD, from the Albert Einstein College of Medicine discussed the results of research done on the topic and what it can mean for providing care for these patients during the annual Liver Meeting in San Francisco.

As hepatitis C becomes a more treatable condition work is being done to extend the treatment to as many patients as possible, including current and former injectable drug users.

Related Videos
Ankeet Bhatt, MD, MBA | Credit: X.com
Sara Saberi, MD | Credit: University of Michigan
Andrew Talal, MD | Credit: University at Buffalo
Muthiah Vaduganathan, MD, MPH | Credit: Brigham and Women's Hospital
Veraprapas Kittipibul, MD | Credit: X.com
Andrew Talal, MD | Credit: University at Buffalo
Square thumbnail featuring headshots of Gursimran Kochhar, MD; Frank Colangelo, MD; Thomas Imperiale, MD; and Michael Sapienza
Square thumbnail featuring headshots of Gursimran Kochhar, MD; Frank Colangelo, MD; Thomas Imperiale, MD; and Michael Sapienza
Square thumbnail featuring headshots of Gursimran Kochhar, MD; Frank Colangelo, MD; Thomas Imperiale, MD; and Michael Sapienza
Square thumbnail featuring headshots of Gursimran Kochhar, MD; Frank Colangelo, MD; Thomas Imperiale, MD; and Michael Sapienza
© 2024 MJH Life Sciences

All rights reserved.